More insights and business value , fewer privacy risks.
Data plays a crucial role in developing effective strategies to tackle healthcare challenges. Leveraging the power of data is invaluable in addressing global infectious diseases, non-communicable diseases, and numerous other issues.
IQVIA is a leading global provider of advanced analytics, technological solutions, and clinical research services to the life sciences industry. The company creates intelligent connections across all aspects of healthcare with analytics, transformative technology, big data, and extensive domain expertise.
IQVIA Connected Intelligence™ delivers insights that can accelerate the clinical development and commercialization of innovative medical treatments, ultimately improving healthcare for patients. IQVIA operates in more than 100 countries with approximately 86,000 employees worldwide.
Privacy limits access to data
Linking healthcare data enhances patient health outcomes. Hospitals, governments, pharmaceutical companies, and research institutions all collect various pieces of patient data. Whether the data is in an application like CTCue or collected via pharmacy prescriptions, combining these fragments of information offers immense value. However, patient data is highly personal and must be used with the utmost respect for privacy, adhering strictly to GDPR regulations. This privacy legislation, however, also limits the data-driven innovation needed.
Valuable research and analysis opportunities are lost
The impact of these limitations is significant. For instance, data can only be stored for two years, causing the loss of valuable basic information. Its use is also subject to restrictions. For some applications, this data cannot be used, resulting in lost research or analysis opportunities. Even anonymizing data through methods like data masking or pseudonymization is not an option, as this poses traceability risks.
Can synthetic data from BlueGen.ai enable IQVIA to innovate and improve healthcare quality? By analysing and sharing privacy-sensitive data in a secure way after all?
IQVIA uses the BlueGen.ai software to generate a complete synthetic dataset, for tabulated patient characteristics and multivariate time-series treatment pathways. The company has tested the extent to which the synthetic data is able to answer different questions with the same results as the real data. For example, the average treatment time, the average time per medication per population, and the time needed for patients to switch medications. The success of new drugs in terms of market share was also tested.
Option 1
Option 2
IQVIA's conclusions in reviewing synthetic data
Good synthetic data does not lead to different business answers.
It would make no difference to use a synthetic or real LRx data set for these business questions.
Synthetic data offers new opportunities.
New opportunities to share insights
Synthesized data from BlueGen.ai allows IQVIA data experts to work with data without privacy risks for research, analysis, and predictions. This opens new opportunities to share valuable data and insights.
Share ICU data safely
Synthetic patients that match the real cohort but
Exploring and developing new innovative activities for services
Safeguarding privacy
“Good synthetic data does not lead to different business answers. It makes no difference to use a synthetic or real dataset. Synthetic data offers new commercial opportunities and research possibilities”
Dennis van der Hoeff,
Innovation Manager